# Study of Disitamab Vedotin and Anlotinib in Patients With HR-Negative, HER2-Low-Expressing Metastatic Breast Cancer

> **NCT06000033** · PHASE2 · UNKNOWN · sponsor: **Qilu Hospital of Shandong University** · enrollment: 35 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Disitamab Vedotin+Anlotinib

## Key facts

- **NCT ID:** NCT06000033
- **Lead sponsor:** Qilu Hospital of Shandong University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-08-10
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2023-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06000033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06000033, "Study of Disitamab Vedotin and Anlotinib in Patients With HR-Negative, HER2-Low-Expressing Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06000033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*